Known targets — ChEMBL curated mechanism
ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | TRPM8 | Q7Z2W7 | 8/20 | 0.48 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.48 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.48 |
| ▸ | GABBR1 | Q9UBS5 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | LPAR3 | Q9UBY5 | 3/20 | 0.42 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL28434387 | 0.94 | HPGD (0.52) | HPGDSMN1; SMN2TRPM8GABBR2GABRR1 | |
| SCHEMBL152127 | 0.94 | HPGD (0.56) | HPGDSMN1; SMN2TRPM8GABBR2GABRR1 | |
| Water SCHEMBL32685216 | 0.90 | HPGD (0.54) | HPGDSMN1; SMN2TRPM8GABBR2GABRR1 | |
| Hydrochloric Acid SCHEMBL28443502 | 0.88 | HPGD (0.52) | HPGDSMN1; SMN2TRPM8GABBR2GABRR1 | |
| SCHEMBL11889581 | 0.88 | HPGD (0.52) | HPGDSMN1; SMN2TRPM8GABBR2GABRR1 | |
| SCHEMBL1726162 | 0.88 | HPGD (0.52) | HPGDSMN1; SMN2TRPM8GABBR2GABRR1 | |
| SCHEMBL10556882 | 0.88 | TRPM8 (0.61) | HPGDSMN1; SMN2TRPM8GABBR2GABRR1 | |
| SCHEMBL28014033 | 0.88 | HPGD (0.52) | HPGDSMN1; SMN2TRPM8GABBR2GABRR1 | |
| SCHEMBL1725975 | 0.88 | HPGD (0.52) | HPGDSMN1; SMN2TRPM8GABBR2GABRR1 | |
| SCHEMBL1725977 | 0.88 | TRPM8 (0.61) | HPGDSMN1; SMN2TRPM8GABBR2GABRR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0351534-B1 | POLYFUNCTIONAL MONOMERS AND PROCESS FOR PRODUCTION THEREOF | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1993-05-12 | — | — | EP | claimed |
| EP-0351534-A2 | Polyfunctional monomers and process for production thereof | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1990-01-24 | — | — | EP | claimed |
| CN-101353313-A | Process to produce oxazolidinones | UPJOHN CO (US) | 2009-01-28 | — | — | CN | disclosed |
| CN-100387581-C | Process for preparing * oxazolidinones | UPJOHN CO (US) | 2008-05-14 | — | — | CN | disclosed |
| CN-1319952-C | Method for preparing oxazolidone amine | PHARMACIA & UPJOHN CO LLC (US) | 2007-06-06 | — | — | CN | disclosed |
| EP-1028940-B1 | PROCESS TO PRODUCE OXAZOLIDINONES | PHARMACIA & UPJOHN CO LLC (US) | 2007-04-18 | — | — | EP | disclosed |
| EP-1328509-B1 | METHODS OF PRODUCING OXAZOLIDINONE COMPOUNDS | PHARMACIA & UPJOHN CO LLC (US) | 2006-03-22 | — | — | EP | disclosed |
| US-6998420-B2 | Oxazolidinone compounds | PHARMACIA & UPJOHN COMPANY (US) | 2006-02-14 | — | — | US | disclosed |
| US-6833453-B2 | As an example, manufacturing a 5-(tert-butylcarbamoyl)-amino-methyl-oxazolidinone by condensing a carbamate with a tert-butylcarbamoyl protected derivative of glycidylamine or a 3-amino-1-halopropanol | PHARMACIA & UPJOHN COMPANY | 2004-12-21 | — | — | US | disclosed |
| CN-1167701-C | Process for preparing oxazolidone amines | �������Ŷ���Լ��������˾ | 2004-09-22 | — | — | CN | disclosed |
| US-20040143131-A1 | in particular,manufacturing a 5-(tert-butylcarbamoyl)-aminomethyl-oxazolidinone by condensing a carbamate with a tert-butylcarbamoyl protected derivative of glycidylamine or 3-amino-1-halopropanol, intermediates | PHARMACIA & UPJOHN COMPANY | 2004-07-22 | — | — | US | disclosed |
| US-20020032348-A1 | Process to produce oxazolidinones | PEARLMAN BRUCE ALLEN (US) | 2002-03-14 | — | — | US | disclosed |
| CN-1275122-A | Process for preparing oxazolidinones | UPJOHN CO (US) | 2000-11-29 | — | — | CN | disclosed |
| CN-1215393-A | Process for preparing oxazolidinones | UPJOHN CO (US) | 1999-04-28 | — | — | CN | disclosed |
| EP-0351534-B1 | POLYFUNCTIONAL MONOMERS AND PROCESS FOR PRODUCTION THEREOF | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1993-05-12 | — | — | EP | disclosed |
| US-4980497-A | GIVE RESINS HAVING HIGH TRANSPARENCY, SURFACE HARDNESS, AND HEAT RESISTANCE; GLAZING MATERIALS, OPTICAL LENSES AND DISC SUBSTRATES | MITSUI TOATSU CHEMICALS, INC. (JP) | 1990-12-25 | — | — | US | disclosed |
| EP-0351534-A2 | Polyfunctional monomers and process for production thereof | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1990-01-24 | — | — | EP | disclosed |
| EP-0050827-B1 | 3-(P-ALKYLSULFONYLPHENYL)-AND 3-(P-ALKYLSULFINYLPHENYL)OXAZOLIDINONE DERIVATIVES AS ANTI-BACTERIAL AGENTS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1986-04-30 | — | — | EP | disclosed |
| US-4340606-A | 3-(p-Alkylsulfonylphenyl)oxazolidinone derivatives as antibacterial agents | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1982-07-20 | — | — | US | disclosed |
| EP-0050827-A1 | 3-(p-Alkylsulfonylphenyl)-and 3-(p-alkylsulfinylphenyl)oxazolidinone derivatives as anti-bacterial agents | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1982-05-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040143131-A1 | in particular,manufacturing a 5-(tert-butylcarbamoyl)-aminomethyl-oxazolidinone by condensing a carbamate with a tert-butylcarbamoyl protected derivative of glycidylamine or 3-amino-1-halopropanol, intermediates | TET1, NAT10, TET3 | HPGD 591/4885SMN1; SMN2 3257/4885TRPM8 4479/4885 |
| US-20020032348-A1 | Process to produce oxazolidinones | ADH1A, ADH5, ADH1C | HPGD 193/4885SMN1; SMN2 2113/4885TRPM8 4872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.